A study published in Nature reports that danshensu, a compound derived from the herb Danshen, reduces osteoporosis associated with type 2 diabetes. According to Nature, the effect works through the PI3K/AKT/Nrf2 signaling pathway. The findings were published on Sunday, September 27, 2026.
The research points to a specific biological route behind the compound's activity. Nature reports that the PI3K/AKT/Nrf2 pathway is central to how danshensu attenuates the bone condition tied to type 2 diabetes. The headline and summary of the study do not detail the experimental methods, dosages, or whether the work involved animal models or human participants.
Osteoporosis is a known complication in people with type 2 diabetes, a condition in which bone strength can decline even as other metabolic markers are managed. Danshensu comes from Danshen, a traditional herb, and the Nature study frames its potential role specifically around diabetes-related bone loss rather than osteoporosis in general.
The study's scope, as described in the available material, is limited to identifying the signaling pathway involved. No clinical recommendations follow from the headline and summary alone, and Nature's report does not include data on human trials or approved treatments.
What to watch next: whether follow-up research moves beyond pathway identification toward animal and human studies that test whether danshensu can meaningfully protect bone health in people with type 2 diabetes.
